On May 27, 2020 Immutep Limited (ASX: IMM; NASDAQ: IMMP) reported that it will host a global webcast on Tuesday 2 June 2020 at 7.30am, Australia Eastern Standard Time (AEST) / Monday 1 June 2020 at 5.30pm, Eastern Daylight Time (EDT) (Press release, Immutep, MAY 27, 2020, View Source [SID1234558594]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
CEO Marc Voigt, CSO and CMO, Dr Frederic Triebel and Director Clinical Development, Christian Mueller will provide an overview of the data from its ongoing Phase II TACTI-002 study and the first interim data from its ongoing INSIGHT-004 Phase I clinical trial, as presented via virtual posters at the 2020 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Virtual Annual Meeting followed by analyst Q&A.
Webcast Details
Date & Time:
Tuesday 2 June 2020 at 7.30am, Australia Eastern Standard Time (AEST)
/ Monday 1 June 2020 at 5.30pm, Eastern Daylight Time (EDT)
Register:
Interested parties can register via a link to the webcast on the Company’s website or via the following link:
View Source
Questions:
Investors are invited to submit questions in advance via [email protected].
A replay of the webcast will be available after the event at www.immutep.com.